Dosages
Side effects in children
Warnings & precautions in children
Contra-indications in children

Interactions
PK
Renal impairment
References

Medroxyprogesterone

Generic name
Medroxyprogesterone
Brand name
ATC Code
G03AC06

Pharmacokinetics in children

There is no specific data known about adolescents.

A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.

dose recommendation of formulary compared to licensed use (on-label versus off-label)

No information is present at this moment.

A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.

Available formulations

No information is present at this moment.

A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.

Dosages

Prevention of endometrial hyperplasia in oestrogen treatment for puberty induction or growth inhibition
  • Oral
    • ≥ 12 years
      • 5 - 10 mg/day in 1 dose
      • Duration of treatment:

        During the first 10-14 days of the month
Contraception
  • Subcutaneous
    • After menarche, ≥ 12 years
      • 104 mg/dose once every 13 weeks.

      • If other contraceptives cannot be considered.
        Administer in the fornt side of the thigh or in the (lower) abdomen.

  • Intramuscular
    • After menarche, ≥ 12 years
      • 150 mg/dose once every 12 weeks.

      • If other contraceptives cannot be considered.
        Administer in the buttock muscle or alternatively in the upper arm.

A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.

Renal impaiment in children > 3 months

Adjustment in renal impairment as specified:

GFR 50-80 ml/min/1.73 m2
Caution is needed in renal function disorders because medroxyprogesterone can cause poor fluid retention.
GFR 30-50 ml/min/1.73 m2
Caution is needed in renal function disorders because medroxyprogesterone can cause poor fluid retention.
GFR 10-30 ml/min/1.73 m2
Caution is needed in renal function disorders because medroxyprogesterone can cause poor fluid retention.
GFR < 10 ml/min/1.73 m2
generalized recommendations cannot be given. An assessment must be made per patient of the desired effect against the risks of side effects on overdosing and failure of the therapy on underdosing.

A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.

The complete list of all undesirable drug reactions can be found in the national Summary of Product Characteristics (SmPC) – click here

Side effects

No information is present at this moment.

A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.

The complete list of all contra-indications can be found in the national Summary of Product Characteristics (SmPC) – click here

Contra-indications

No information available on specific contra indications in children.

The complete list of all warnings and precautions can be found in the national Summary of Product Characteristics (SmPC) – click here

Warnings & precautions in children

In adolescent females, use is only indicated if other contraceptive methods are considered unsuitable or unacceptable due to the unknown long-term effects on bone density during the critical period of bone growth. [SmPC SAYANA®]

A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.

Interactions

The complete list of all interactions can be found in the national Summary of Product Characteristics (SmPC) – click here

A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.

A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.

References

  1. Pfizer BV, SmPC Sayana (RVG 35305) 01-07-2023, www.cbg-meb.nl
  2. Pfizer BV, SPC Depo-Provera (RVG 06602) 26-03-2020, www.geneesmiddeleninformatiebank.nl
  3. Noordam C et al, Werkboek Kinderendocrinologie, digitale publicatie op www.nvk.nl (alleen leden), 2010
  4. Pfizer, SmPC Depo-Clinovir 150mg Injektionssuspension (2704.00.02), 08/2016
  5. Pfizer, SmPC Sayana 104mg/0,65ml Injektionssuspension (69347.00.00), 06/2016
  6. Rangaupharm, SmPC Depo-Progevera 150mg Injektionssuspension (97378.00.00), 08/2016

A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.

Changes

Changes